Company: BLCO
Filing Date: 2025-10-29
Form Type: 10-Q
Source: 0001860742-25-000023
Chunk: 119

Company: Bausch & Lomb Corp
Filing Date: 2025-10-29
Form: 10-Q
Item: Item 2
Chunk 119
---
udited interim Condensed Consolidated Financial Statements included elsewhere in this Form 10-Q, as well as Note 19, “LEGAL PROCEEDINGS” of our audited Consolidated Financial Statements for the year ended December 31, 2024, included in our Annual Report, for further details regarding certain of these infringement proceedings.The risks of generic competition are a fact of the eye health industry and are not specific to our operations or product portfolio. These risks are not avoidable, but we believe they are manageable. To manage these risks, our leadership team routinely evaluates the impact that generic competition may have on future profitability and operations. In addition to aggressively defending our patents and other intellectual property, our leadership team makes operational and investment decisions regarding these products and businesses at risk, including decisions regarding our pipeline. Our leadership team actively manages our pipeline in order to identify innovative and realizable projects that are expected to provide incremental and sustainable revenues and growth into the future. We believe that we have a well-established product portfolio that is diversified within our core businesses. We also believe that we have a robust pipeline that not only provides for the next generation of our existing products, but also brings new solutions into the market.See the section entitled “Risk Factors” included in our Annual Report, for additional information on the risks associated with our intellectual property and our competition risks.

39

RESULTS OF OPERATIONSOur unaudited operating results for the three and nine months ended September 30, 2025 and 2024 were as follows:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,(in millions)20252024Change20252024ChangeRevenuesProduct sales$1,277 $1,192 $85 $3,682 $3,499 $183 Other revenues4 4 — 14 12 2 1,281 1,196 85 3,696 3,511 185 ExpensesCost of goods sold (excluding amortization and impairments of intangible assets)509 464 45 1,513 1,369 144 Cost of other revenues1 — 1 4 2 2 Selling, general and administrative (Note 4)528 511 17 1,670 1,550 120 Research and development95 84 11 277 250 27 Amortization of intangible assets68 72 (4)202 220 (18)Other (income) expense